Q-omics provides the consensus-scored LCMT1-AS2 profile across patient tissues and cancer cell-line models. LCMT1-AS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LCMT1-AS2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, LCMT1-AS2 RNA expression shows 18,327 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where LCMT1-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCMT1-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCMT1-AS2 survival associations across molecular data types. LCMT1-AS2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCMT1-AS2 RNA expression–survival associations across cancer types. High LCMT1-AS2 expression shows unfavorable associations in COAD, THCA, CESC and LIHC, but favorable associations in ESCA and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for LCMT1-AS2 RNA expression.
This table summarizes LCMT1-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LCMT1-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCMT1-AS2 shows lower tumor expression in KICH, KIRP, KIRC and UCEC and higher tumor expression in HNSC and CHOL. The KICH box plot shows higher LCMT1-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.118, t-test p < 0.001).
This table shows molecular features associated with LCMT1-AS2 in patient tissues and cancer cell lines. In patient samples, LCMT1-AS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
